Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Completed · Phase 2
Conditions studied: Breast Cancer
In brief
The purpose of this research study is to : * Determine how effective cisplatin or carboplatin is in slowing the time it takes for ER negative (estrogen-receptor-negative), PR negative (progesterone receptor-negative), HER2 negative (human epidermal growth factor receptor 2) breast cancer to progress. Cisplatin and carboplatin are anti-cancer chemotherapy drugs that stop cancer cells from growing abnormally and is used to treat other cancers. * Evaluate a new biomarker to help determine which breast cancers are most likely to respond to cisplatin chemotherapy The hypothesis is that Triple Negative metastatic breast cancer may be particularly sensitive to platinum, and that a subgroup of those patients may have a marker in their tumors that predicts response.
Key facts
- Study ID
- NCT00483223
- Run by
- Massachusetts General Hospital
- People needed
- 86
- Starts
- 2007-06-01
- Expected to finish
- 2017-06-01
- Last updated by the study team
- 2017-08-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed invasive breast cancer with stage IV disease, according to AJCC 6th edition (American Joint Committee on Cancer), either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological study
- All tumors must be ER-, PGR- and HER2-negative
- 18 years of age or older
- Paraffin tissue block is required from the primary tumor tissue or from diagnostic metastatic biopsy at time of relapse
- Measurable disease by RECIST
- Performance status of 0,1 or 2 by ECOG criteria (Eastern Cooperative Oncology Group)
- Life expectancy greater than 12 weeks
- Normal organ and bone marrow function documented within 14 days prior to enrollment as defined by the protocol
You may not qualify if…
- More than 1 prior chemotherapy for the treatment of recurrent or metastatic breast cancer
- Prior treatment with cisplatin, carboplatin, or other platinum chemotherapy agents
- Active brain metastases or unevaluated neurological symptoms suggestive of brain metastases
- Intercurrent illness or other major medical condition or comorbid condition that might affect study participation
- Significant history of uncontrolled cardiac disease such as uncontrolled hypertension, unstable angina, recent myocardial infarction, uncontrolled congestive heart failure, cardiomyopathy either symptomatic or asymptomatic but with decreased ejection fraction <45%
- Renal dysfunction for which cisplatin dose would either require dose modification or would be considered unsafe
- Pregnant or nursing women
- History or other malignancy that was not treated with curative intent
Where it is running
- University of Alabama-Birmingham — Birmingham, Alabama, United States
- UCSF — San Francisco, California, United States
- Georgetown - Lombardi Cancer Center — Washington D.C., District of Columbia, United States
- Johns Hopkins University Medical Center — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- North Shore Medical Center — Peabody, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- University of North Carolina — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.